Description,Qualitative Measure,Measurement Inequality,Quantitative measurement,Units,Allele Name,MHC allele class,Ref Type,Ref Date,Ref Title,Assay Method,Assay Group,Host Name,Description_Length,Normalized_QM
KLVVVGAVGV,Positive,=,35810.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.030850523240273375
LLVVGAAGV,Positive,=,17540.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.09681705030808807
LLVVGARGV,Positive,=,23700.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.06899845243249825
LLVVGAVGV,Positive,=,25560.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.06201553842241093
LLVVVGARGV,Positive-High,=,6550.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.1878557861679665
YLVVGAAGV,Positive,=,16410.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.10297180506290493
YLVVGACGV,Positive,=,26090.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.060118690899308214
YLVVGADGV,Positive,=,13420.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.12156227598302373
YLVVGARGV,Positive,=,15600.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.10765027346733093
YLVVGASGV,Positive,=,21170.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.07943211937343453
YLVVGAVGV,Positive,=,22950.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.07197051995451631
YLVVVGAAGV,Positive,=,27740.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.05445098550589855
YLVVVGADGV,Positive-High,=,5683.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.2009785862475908
YLVVVGASGV,Positive,=,10650.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.14292927938282607
YLVVVGAVGV,Positive,=,15470.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.10842369501540217
YVVVGAVGV,Positive,=,28260.0,nM,HLA-A*02:01,I,Literature,2022,Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.05273450279419134
EAAGIGILTV,Positive,,22500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.07380074482379229
SLLMWITQC,Positive,,4450.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.22358303891823672
EAAGIGILTVI,Positive,,30700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),11,0.04508043862024291
ELAGIGILTV,Positive,,2480.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2776179295262677
EMAGIGILTV,Positive,,3600.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.24317403654722725
EIAGIGILTV,Positive,,3350.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2498260674607251
EVAGIGILTV,Positive,,4210.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2287071225201845
ELAGIGILTL,Positive,,4170.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2295894522345869
ELAGIGILTA,Positive,,5610.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.202173485296401
ELAGIGILTI,Positive,,2930.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2622069055229073
ELAGIGILTM,Positive,,36800.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.028330077770162613
EMAGIGILTL,Positive,,4380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.22504844526696371
EMAGIGILTA,Positive,,3620.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.2426619945968299
EMAGIGILTI,Positive,,1790.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.30775190563500243
EMAGIGILTM,Positive,,37500.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),10,0.026588536741671498
SLLMWITQA,Positive,,1090.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3535973851423163
SLLMWITQL,Positive,,1970.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2988960935861278
SLLMWITQV,Positive,,1190.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3454848703961633
SLLMWITQM,Positive,,2380.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2814218958748952
SLLMWITQI,Positive,,1360.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.33314345367629183
SALMWITQA,Positive,,2280.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2853891716904157
SALMWITQL,Positive,,1990.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2979625166013703
SALMWITQV,Positive,,1700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.31251978233584243
SALMWITQM,Positive,,11400.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1366395513074301
SALMWITQI,Positive,,2030.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2961231855361516
SMLMWITQA,Positive,,950.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3663029126508308
SMLMWITQL,Positive,,1340.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3345127133224426
SMLMWITQV,Positive,,1010.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3606425725190039
SMLMWITQM,Positive,,1570.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.31987230191718885
SMLMWITQI,Positive,,710.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3932163120666763
SILMWITQA,Positive,,1920.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3012721456672733
SILMWITQL,Positive,,5420.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.20535792246113427
SILMWITQV,Positive,,1060.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3561768084339461
SILMWITQM,Positive,,3100.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2569942581858182
SILMWITQI,Positive,,2700.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.26976257328889863
GILGFVFTL,Positive,,1020.0,nM,HLA-A*02:01,I,Literature,2023,"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.",cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3597319904179632
LLAAPSAMA,Positive-Intermediate,,37120.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.02752987073120794
AAVTSQFPV,Positive-Intermediate,,27710.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.054550992731865366
LMAVEEREV,Positive-Intermediate,,34110.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.03534567889885698
GLMKGGANL,Positive-Intermediate,,16990.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.099761570096086
MLREQLDQV,Positive-Intermediate,,13870.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.11851396002716652
TLHGFVNHI,Positive-Intermediate,,10650.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.14292927938282607
RILSCLSDL,Positive-Intermediate,,29320.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.04933124453934112
GLLHKVKEL,Positive-Intermediate,,30140.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.046781902449804624
ALLVVSREL,Positive-High,,5522.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.2036347542439748
WLAKTRVFL,Positive-High,,5871.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.19797060272782152
ILCKDLSTV,Positive-High,,9327.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.15518890882475578
FLTDVACRV,Positive-High,,5380.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.20604254289263926
AVLERYLEL,Positive-High,,5962.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1965490377225576
MQSLHFAFL,Positive-Intermediate,,47660.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.004429899809186511
ALEAVRIEL,Positive-High,,5843.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.19841244297482874
TLHDIWPEI,Positive-High,,9314.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.15531781859978788
GLYDVQLTI,Positive-Intermediate,,31720.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.04205960572382483
ALLSNDNAL,Positive-High,,8692.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1617057112487147
LLPMSLHWFI,Positive-Intermediate,,38820.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.023391184277033128
LLFAKFSFLI,Positive-Intermediate,,19150.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.08870055047101177
RQLLFSLLAV,Positive-Intermediate,,24610.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.06551614297370212
SLNVDTAFPL,Positive-Intermediate,,45060.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.009614621269452228
TLAGHVYEYI,Positive-Intermediate,,48080.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.003618994231851636
KLIASILYQA,Positive-Intermediate,,16220.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.10404815395921384
FLIHSSTGLI,Positive-Intermediate,,39570.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),10,0.02162260111816749
GILGFVFTL,Positive-High,,7048.0,nM,HLA-A*02:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.18108311143651634
YLQPRTFLL,Positive,,75.0,nM,HLA-A*02:01,I,Literature,2023,Coarse-grained molecular dynamics-guided immunoinformatics to explain the binder and non-binder classification of Cytotoxic T-cell epitope for SARS-CoV-2 peptide-based vaccine discovery.,binding assay,dissociation constant KD,Homo sapiens (human),9,0.6009633469331641
GLYPQLSAI,Positive,,5.9,nM,HLA-A*02:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8359529831152714
QLSAIALGV,Positive,,3.9,nM,HLA-A*02:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.8742140072226278
SMPELSLTLFDEPPPLVETEPLPPLSDV,Positive,,3830.0,nM,HLA-A*02:01,I,Literature,2024,Diverse cytomegalovirus US11 antagonism and MHC-A evasion strategies reveal a tit-for-tat coevolutionary arms race in hominids.,purified MHC/competitive/fluorescence,dissociation constant KD (~IC50),Homo sapiens (human),28,0.2374501708539973
